Tunica, yup, the pharms don't uniformly sell single doses of Muse....
because they don't know they can or, as you suggest,they choose sales over service. Business 101.
My interest in single dose sales relates to customer satisfaction.
If,for any reason, a new Muse customer (defined as a patient who has not reported theraputic success)becomes uncomfortable at the point of purchase, Vivus has a problem, not the pharmacy. Marketing 101.
I have to imagine that it takes as much guts to make the first trip to the pharmacy as it did to make that first doctors appointment. What would you feel Tunica if you discovered that your prescribed Muse strength was ineffective and the remaining 5 doses in your six-pack (each one worth roughly one month of cablevision or a share of Zona)was nonreturnable? If first impressions are important, that ones a stinker.
Also, positioning will be real important as soon as the medical world has several ED products on tap. Personally, I would like to see Muse positioned front- of- mind with docs, pharms, patients, the media at large and Esquire Magazine. Uh, huh. Positioning, at it's most lethal might look like this: quickly name a competitor of Vaseline, Scotch Tape, Xerox, or Q-Tips? How about name the second highest mountain in the world, or who were the next guys to fly after the Right Brothers, or name another doctor besides Tunica that posts to this thread? :-)
I gather the existing policies regarding single dose sales would forever prevent customers being stuck with unwanted product. Until that policy is uniformly understood and followed, Vivus has a problem that is getting bigger...that means I have a problem because I own stock, and Tunica has a problem, because he (finally) owns stock (again).<grin>
I believe that the Vivus 4th quarter advertising campaign could begin to solve some of these concerns by mentioning single dose samples and sales. But, it's up to Vivus to make it happen. When production limitations are no longer a problem, (late December) I anticipate Vivus putting a bunch more feet on the street. These reps, along with advertising support, will solidly position Muse with a growing circle of docs and disciplines, countries and continents. Won't that be fun?
I am really tired of this particular issue which is in concert with your request to "stop beating a dead horse." But isn't beating a dead horse at the very core of this ED thing in the first place? :-)
Frostman |
